Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-03-06
2007-03-06
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C558S482000, C558S483000, C558S488000
Reexamination Certificate
active
10048469
ABSTRACT:
Compounds or their salts of general formula (I): A—B—N(O)swherein: s is an integer equal to 1 or 2; A=R—T1—, wherein R is the drug radical and T1=(CO)tor (X)t′, wherein X=O, S, NR1c, R1cis H or a linear or branched alkyl or a free valence, t and t′ are integers and equal to zero or 1, with the proviso that t=1 when t′=0; t=0 when t′=1; B=—TB—X2—O— wherein TB=(CO) when t=0, TB=X when t′=0, X being as above defined; X2is equal to R1B—X—R2Bradical wherein X is as above defined, R1Band R2B, equal to or different from each other, are linear or branched C1–C6alkylenes, or X2is a radical wherein two alkylene chains C1–C4are linked to nonadjacent positions of a central ring having 4 or 6 atoms, said ring being an unsaturated cycloaliphatic ring, or a saturated or aromatic heterocylic ring, containing one or two heteroatoms, equal or different, selected from O, S, N; wherein the unsaturated cycloaliphatic ring does not have aromatic character according to Huckel's rule.
REFERENCES:
patent: 5597847 (1997-01-01), Matji et al.
patent: 5700947 (1997-12-01), Soldato
patent: 5861426 (1999-01-01), Del Soldato et al.
patent: 6242432 (2001-06-01), Del Soldato
patent: 0 012 866 (1980-07-01), None
patent: 218 923 (1994-09-01), None
patent: 98/15568 (1998-04-01), None
McCance & Huether; Pathophysiology: The Biologic Basis for Disease in Adults and Children, Third Edition (1988) pp. 48-54.
McCance & Huether; Pathophysiology: The Biologic Basis for Disease in Adults and Children, Third Edition (1988) pp. 71-77.
McCance & Huether; Pathophysiology: The Biologic Basis for Disease in Adults and Children, Third Edition (1988) p. 1025.
K. Schwartz; Free Radical Biology & Medicine, vol. 21, No. 5, pp. 641-649 (1996); “Oxid ative Stress During Viral Infection: A Review”.
F. Silverstein et al.; Annals of Internal Medicine, vol. 123, No. 4, pp. 241-249 (1995); Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs.
Martindate: The Extra Pharmacopoeia; 31st Edition; Royal Pharmaceutical Society (1996), p. 73.
Current Medical Diagnosis & Treatment 1998, 37th Edition; pp. 431 and 794.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, (1996); pp. 1459-1465 and 1474.
Martindate: The Extra Pharmacopoeia; 30th Edition; Royal Pharmaceutical Society (1993), pp. 712-723, partially illegible.
H. Utley et al.; Archives of Biochemistry and Biophysics, 118, pp. 29-32 (1967); “E ffect of Sulfhydryl Reagents on Peroxidation in Microsomes”.
C. Baylis et al.; J. Clin. Invest., 90, pp. 278-281 (1992); “Ch ronic Blockade of Nitric Oxide Synthesis in the Rat Produces Systemic Hypertension and Glomerural Damage”.
M. Facino et al.; Drugs Exptl. Clin. Res. XXIII (5/8) pp. 157-165 (1997); “Hyd roxynimesulide, the Main Metabolite of Nimesulide, Prevents Hydroperoxide/Hemoglobin-Induced Hemolysis of Rat Erythrocytes”.
B. Haliwell and J. Gutteridge; Free Radicals in Biology and Medicine, 2nd Edition pp. 86 and 416 (1989).
Greene and Wuts; Protective Groups In Organic Synthesis, Second Edition (1980), title page only.
Remington's Pharmaceutical Sciences; 15th Edition (1975), title page only.
Hermann et al.; Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, No. 12, pp. 3588-3592 (1997) “S hear Stress Inhibits H2O2-Induced Apoptosis of Human Endothelial Cells by Modulation of the Glutathione Redox Cycle and Nitric Oxide Synthase”.
Cirino et al., “Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal sparing properties”, British Journal of Pharmacology, vol. 117, No. 7, Apr. 1996 pp. 1421-1426.
Benoni et al., “Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method”, Journal of Pharmaceutical Sciences, vol. 84, No. 1, Jan. 1995, pp. 93-95.
Arent & Fox PLLC
Nicox S.A.
Zucker Paul A.
LandOfFree
Pharmaceutical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3722798